Protein–protein interactions among m6A regulators and their prognostic significance in prostate cancer are depicted in Fig. 1C. A previous study revealed that tumors with poor FTO expression displayed low “writer” expression (including KIAA1429, METTL14, RBM15, RBM15B, ZC3H13, RBMX, and CBLL1) but high METTL3 expression [19]. Here, VIRMA is linked to prostate cancer.